Navigation Links
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process
Date:9/15/2009

ROCKVILLE, Md., Sept. 16 /PRNewswire-USNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million. This new funding will facilitate efforts to increase the efficiency and scale-up of manufacturing and release processes to the levels required for Phase 3 clinical testing, licensure, and commercial launch of Sanaria(TM) PfSPZ, Sanaria's attenuated whole parasite malaria sporozoite vaccine.

Sanaria(TM) PfSPZ Vaccine entered Phase 1 clinical trials of safety and efficacy at the Naval Medical Research Center and the University of Maryland School of Medicine's Center for Vaccine Development in the spring of 2009. Since 2003, peer-reviewed NIAID SBIR grants have provided Sanaria with over $17 million in financial support.

About Sanaria(TM) PfSPZ Vaccine

Sanaria(TM)( )PfSPZ Vaccine consists of live sporozoite-stage Plasmodium falciparum parasites weakened (attenuated) by exposure to radiation. Such sporozoites, delivered to human volunteers by the bite of infected mosquitoes, have been shown to confer protection against malaria. Sanaria has developed novel technologies and facilities to successfully translate research findings from a handful of volunteers receiving mosquito-administered sporozoites to a bona fide vaccine that can be clinically tested and conventionally administered to hundreds of millions of recipients. Although live, attenuated pathogens are commonly used to vaccinate against many viral and bacterial diseases, the Sanaria(TM)( )PfSPZ Vaccine is unique among vaccines designed to prevent malaria. For the first time, an immunogen conferring high levels of protection against malaria has been formulated as a stable, injectable vaccine candidate that meets regulatory standards.

About Sanaria Inc.

Sanaria Inc. was founded in 2003. The company's primary mission is to develop and commercialize attenuated whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include the assessment of the vaccine candidate, the expectations for immunity of the vaccine, and belief concerning the measure of success. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third-parties, clinical trials results, and the ability to commercialize the vaccine.

For further information contact:

Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750


'/>"/>
SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
2. KV Pharmaceutical Receives Stockholder Action by Written Consent
3. gloStreams gloEMR Version 5.0 Receives 08 CCHIT Certification
4. Center for AIDS Intervention Research Medical receives $11.16 million NIH grant
5. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
6. Digestive Care, Inc. Receives Complete Response Letter from FDA for PANCRECARB(R) (pancrelipase)
7. COLD-FX(R) Receives Highest Sports Certification in North America
8. Project Lifesaver International Receives Federal Assistance for the Missing Alzheimers Patient Assistance Program
9. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
10. UM receives grant to support graduate students in the family nurse practitioner program
11. Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology: